Lilly and Novo Accused of Blocking Telehealth to Suppress Cheaper GLP-1 Versions

A lawsuit filed by Strive Specialties alleges Eli Lilly and Novo Nordisk blocked telehealth partners to curb compounded GLP-1 therapies, potentially impacting about 1.5 million U.S. patients who rely on cheaper, personalized versions of Wegovy/Ozempic. The plaintiffs say these agreements limit prescriber choice and patient access, while the drugmakers argue the deals target mass-produced copies. Novo Nordisk has highlighted the past Hims & Hers partnership ended after compounded Wegovy issues, and Lilly labeled the suit a bid to divert attention from Strive’s own conduct. The case underscores ongoing tensions between compounded vs. branded GLP-1 drugs, access, and pricing in the weight‑loss market.